The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC

Inclusion Criteria: * Serologic evidence of HVC infection by an anti-HCV antibody test. * Serum HCV RNA quantifiable \> 20,000 copies/mL at screening period and demonstrate abnormal ALT \> 40 for 6 months. * No clinical suspicion or radiological evidence of hepatocellular carcinoma and a serum AFP \< 50 ng/mL. * Negative urine pregnancy test for women of childbearing potential documented within the 24-hour period prior to the first dose for test drug. Exclusion Criteria: * Interferon with or without RBV therapy at any previous time or any other systemic antiviral therapy or investigational drug \> 3 months prior to the first dose of study drug. * Subjects who are expected to need systemic antiviral therapy at any time during the study are also excluded. * Positive test at screening for anti-HAV 1gM Ab, HbsAg, anti-HBc IgM Ab, or anti-HIV Ab. * Documented serum concentrations of ceruloplasmin or Alpha 1-antitrypsin consistent with an increased risk of metabolic liver disease. * History or other evidence of a medical condition associated with chronic liver disease (e.g., haemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures). * Women with ongoing pregnancy or breast feeding * Neutrophil count \< 1000 cells/mm3, Hgb \<11 g/dL in women or 12 g/dL in men, or platelet count \< 80,000 cells/mm3. * Serum creatinine level \> 2 times the upper limit of normal at screening. * Evidence of alcohol and/or drug abuse within one year of entry. * History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquillizer at therapeutic doses for major depression or psychosis, respectively, for at least 4 months at any previous time or any history of the following: * a suicidal attempt * hospitalization for psychiatric disease, OR * a period of disability due to a psychiatric disease. * History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematous, autoimmune hemolytic anemia, scleroderma, severe psoriasis, sarcoidosis, etc.). * History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease including ascites or hepatic encephalopathy. * History or other evidence of chronic pulmonary disease associated with functional limitation. * History of severe cardiac disease. * History of a severe seizure disorder or current anticonvulsant use. * Evidence of an active or suspected cancer or a past history of malignancy other than skin cancer. * History of having received any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) ≤ 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study. * History of major organ transplantation with an existing functional graft. * History of thyroid disease poorly controlled on prescribed medications. * History or other evidence of severe retinopathy. * Inability or unwillingness to provide informed consent or abide by the requirements of the study. * History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.